AUTL Earnings & Financial Statements
Autolus Therapeutics plc
$1.71
+$0.02(+1.18%)
39
Overall
60
Value
18
Tech
39
Quality
Market Cap
$449.81M
Volume
826.38K
52W Range
$1.18 - $2.58
Target Price
$8.69
AUTL earnings and financial statements: Autolus Therapeutics plc's income statement, balance sheet and cash flow statement, annual and quarterly.
AUTL Annual Financial Statements
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | $10.12M | $1.70M | - | - | - |
| Cost of revenue | $11.39M | - | - | - | - |
| Operating income | -$241.43M | -$179.70M | -$143.41M | -$165.00M | -$168.15M |
| EBITDA | -$202.09M | -$156.77M | -$132.24M | -$156.43M | -$160.60M |
| Net income | -$220.66M | -$208.38M | -$148.84M | -$142.10M | -$142.09M |
| EPS (diluted) | $-0.86 | $-1.20 | $-1.57 | $-1.97 | $-2.76 |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $782.73M | $375.38M | $490.27M | $405.56M | $294.24M |
| Total liabilities | $355.40M | $263.91M | $191.60M | $92.24M | $84.20M |
| Shareholders’ equity | $427.32M | $111.47M | $298.67M | $313.32M | $210.03M |
| Cash and equivalents | $227.38M | $239.57M | $382.44M | $310.34M | $153.30M |
| Long-term debt | $49.63M | $47.91M | $19.22M | $16.55M | $50.57M |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$206.27M | -$145.59M | -$112.31M | -$117.86M | -$117.76M |
| Capital expenditure | -$34.82M | -$10.99M | -$10.84M | -$8.86M | -$14.68M |
| Free cash flow | -$241.09M | -$156.57M | -$123.15M | -$126.72M | -$132.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUTL | $1.71 | +1.2% | 826.38K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Autolus Therapeutics plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW